vs
Side-by-side financial comparison of OLAPLEX HOLDINGS, INC. (OLPX) and Vericel Corp (VCEL). Click either name above to swap in a different company.
OLAPLEX HOLDINGS, INC. is the larger business by last-quarter revenue ($105.1M vs $92.9M, roughly 1.1× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs -12.5%, a 37.5% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 4.3%). OLAPLEX HOLDINGS, INC. produced more free cash flow last quarter ($32.6M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 3.1%).
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
OLPX vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.1M | $92.9M |
| Net Profit | $-13.1M | $23.2M |
| Gross Margin | 68.0% | 78.7% |
| Operating Margin | -4.3% | 24.1% |
| Net Margin | -12.5% | 25.0% |
| Revenue YoY | 4.3% | 23.3% |
| Net Profit YoY | -48.9% | 17.3% |
| EPS (diluted) | $-0.02 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $105.1M | $92.9M | ||
| Q3 25 | $114.6M | $67.5M | ||
| Q2 25 | $106.3M | $63.2M | ||
| Q1 25 | $97.0M | $52.6M | ||
| Q4 24 | $100.7M | $75.4M | ||
| Q3 24 | $119.1M | $57.9M | ||
| Q2 24 | $103.9M | $52.7M | ||
| Q1 24 | $98.9M | $51.3M |
| Q4 25 | $-13.1M | $23.2M | ||
| Q3 25 | $11.1M | $5.1M | ||
| Q2 25 | $-7.7M | $-553.0K | ||
| Q1 25 | $465.0K | $-11.2M | ||
| Q4 24 | $-8.8M | $19.8M | ||
| Q3 24 | $14.8M | $-901.0K | ||
| Q2 24 | $5.8M | $-4.7M | ||
| Q1 24 | $7.7M | $-3.9M |
| Q4 25 | 68.0% | 78.7% | ||
| Q3 25 | 69.1% | 73.5% | ||
| Q2 25 | 71.2% | 73.7% | ||
| Q1 25 | 69.5% | 69.0% | ||
| Q4 24 | 66.3% | 77.6% | ||
| Q3 24 | 68.6% | 71.9% | ||
| Q2 24 | 69.7% | 69.5% | ||
| Q1 24 | 72.1% | 68.9% |
| Q4 25 | -4.3% | 24.1% | ||
| Q3 25 | 3.7% | 5.1% | ||
| Q2 25 | -1.1% | -3.2% | ||
| Q1 25 | 8.7% | -24.3% | ||
| Q4 24 | 3.0% | 24.5% | ||
| Q3 24 | 23.5% | -4.3% | ||
| Q2 24 | 15.7% | -11.5% | ||
| Q1 24 | 19.8% | -10.7% |
| Q4 25 | -12.5% | 25.0% | ||
| Q3 25 | 9.7% | 7.5% | ||
| Q2 25 | -7.3% | -0.9% | ||
| Q1 25 | 0.5% | -21.4% | ||
| Q4 24 | -8.7% | 26.3% | ||
| Q3 24 | 12.4% | -1.6% | ||
| Q2 24 | 5.6% | -8.9% | ||
| Q1 24 | 7.8% | -7.5% |
| Q4 25 | $-0.02 | $0.46 | ||
| Q3 25 | $0.02 | $0.10 | ||
| Q2 25 | $-0.01 | $-0.01 | ||
| Q1 25 | $0.00 | $-0.23 | ||
| Q4 24 | $-0.01 | $0.40 | ||
| Q3 24 | $0.02 | $-0.02 | ||
| Q2 24 | $0.01 | $-0.10 | ||
| Q1 24 | $0.01 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $318.7M | $137.5M |
| Total DebtLower is stronger | $352.3M | — |
| Stockholders' EquityBook value | $879.4M | $354.6M |
| Total Assets | $1.5B | $488.0M |
| Debt / EquityLower = less leverage | 0.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $318.7M | $137.5M | ||
| Q3 25 | $286.4M | $135.4M | ||
| Q2 25 | $289.3M | $116.9M | ||
| Q1 25 | $580.9M | $112.9M | ||
| Q4 24 | $586.0M | $116.2M | ||
| Q3 24 | $538.8M | $101.7M | ||
| Q2 24 | $507.9M | $102.5M | ||
| Q1 24 | $507.5M | $110.6M |
| Q4 25 | $352.3M | — | ||
| Q3 25 | $352.1M | — | ||
| Q2 25 | $351.9M | — | ||
| Q1 25 | $649.1M | — | ||
| Q4 24 | $650.5M | — | ||
| Q3 24 | $651.8M | — | ||
| Q2 24 | $653.1M | — | ||
| Q1 24 | $654.4M | — |
| Q4 25 | $879.4M | $354.6M | ||
| Q3 25 | $888.7M | $321.9M | ||
| Q2 25 | $874.2M | $306.8M | ||
| Q1 25 | $878.3M | $295.5M | ||
| Q4 24 | $874.4M | $292.0M | ||
| Q3 24 | $879.7M | $257.5M | ||
| Q2 24 | $863.3M | $243.0M | ||
| Q1 24 | $855.7M | $233.9M |
| Q4 25 | $1.5B | $488.0M | ||
| Q3 25 | $1.5B | $453.3M | ||
| Q2 25 | $1.5B | $435.6M | ||
| Q1 25 | $1.8B | $424.6M | ||
| Q4 24 | $1.8B | $432.7M | ||
| Q3 24 | $1.8B | $390.4M | ||
| Q2 24 | $1.8B | $376.8M | ||
| Q1 24 | $1.8B | $356.7M |
| Q4 25 | 0.40× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.7M | $15.0M |
| Free Cash FlowOCF − Capex | $32.6M | $12.8M |
| FCF MarginFCF / Revenue | 31.0% | 13.8% |
| Capex IntensityCapex / Revenue | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $58.3M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.7M | $15.0M | ||
| Q3 25 | $8.0M | $22.1M | ||
| Q2 25 | $20.9M | $8.2M | ||
| Q1 25 | $-2.9M | $6.6M | ||
| Q4 24 | $49.7M | $22.2M | ||
| Q3 24 | $33.5M | $10.2M | ||
| Q2 24 | $16.2M | $18.5M | ||
| Q1 24 | $43.7M | $7.2M |
| Q4 25 | $32.6M | $12.8M | ||
| Q3 25 | $7.9M | $19.5M | ||
| Q2 25 | $20.8M | $81.0K | ||
| Q1 25 | $-3.0M | $-7.6M | ||
| Q4 24 | $49.2M | $8.5M | ||
| Q3 24 | $33.3M | $-9.2M | ||
| Q2 24 | $16.1M | $1.8M | ||
| Q1 24 | $43.3M | $-6.8M |
| Q4 25 | 31.0% | 13.8% | ||
| Q3 25 | 6.9% | 28.8% | ||
| Q2 25 | 19.6% | 0.1% | ||
| Q1 25 | -3.1% | -14.5% | ||
| Q4 24 | 48.9% | 11.2% | ||
| Q3 24 | 28.0% | -15.9% | ||
| Q2 24 | 15.5% | 3.4% | ||
| Q1 24 | 43.7% | -13.3% |
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 0.1% | 12.9% | ||
| Q1 25 | 0.0% | 27.0% | ||
| Q4 24 | 0.4% | 18.3% | ||
| Q3 24 | 0.1% | 33.5% | ||
| Q2 24 | 0.1% | 31.8% | ||
| Q1 24 | 0.5% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | 0.72× | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | -6.27× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 2.81× | — | ||
| Q1 24 | 5.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
